Emergency Department point-of-care antiviral host response testing is accurate during periods of multiple respiratory virus co-circulation

FebriDx is a CE-marked, FDA-approved point-of-care test that detects the antiviral host response protein Myxovirus Resistance Protein A (MxA), in addition to C-reactive protein, using finger-prick blood. FebriDx MxA detection had a high negative predictive value for COVID-19 in symptomatic adults presenting to hospital in the first waves of the pandemic and was used subsequently as a ‘rule out’ triage tool in Emergency departments. The diagnostic accuracy of FebriDx MxA in the current context of co-circulation of influenza, SARS-CoV-2, and Respiratory Syncytial Virus (RSV), and in the era of COVID-19 vaccination, is unknown.

Source: Journal of Infection - November 15, 2023 Category: Infectious Diseases Authors: Nathan J Brendish, Cai Davis, Mary Chapman, Florina Borca, Daniel Waddington, Christopher Hill, Nicola White, Tristan W Clark Source Type: research